The cheapest study to win is one whose site list is not finished yet. The sponsor has a protocol, a budget, and a start date, and the people building the list are still looking. That moment is published.
- A trial is registered as not yet recruiting with a start date a few months out and too few sites named to hit its enrollment target.
- A recruiting trial slides past its own completion estimate and starts adding rescue sites.
- A clinical-stage company closes a financing that names the program going into the clinic next.
- A sponsor or CRO posts for a feasibility manager in your therapeutic area.
Reach the person who builds the site list inside that window and the conversation starts before the list closes.
This guide compares seven channels by estimated cost per study award and ends with a 30-day plan.
CRO relationships and preferred site programs
Most commercial trials run through a contract research organization, and every large CRO keeps a site database it searches first when a sponsor asks for coverage.
Getting into that database, and then onto a preferred or partner site program, is the single biggest source of steady awards for most independent sites.
What earns a place:
- Clean performance data. Enrolment against target, screen failure rate, and query resolution time on the studies you already ran for them.
- Fast start-up. A regulatory packet returned in days and a contract that does not sit in legal for a month.
- Honest feasibility. A projection you then hit is worth more than a large one you miss.
The limit is dependence. A site whose whole calendar comes from one CRO has handed its pricing and its timing to someone else.
Sponsor past-performance lists
Sponsors keep their own records of which sites delivered, and an incumbent site with a good record is the first call on the next protocol in the same indication.
Direct cost is close to zero once the relationship exists. The catch is that it only exists after you have run a study for that sponsor, which is exactly the problem a new or growing site is trying to solve.
The practical move is to treat every current study as the sales call for the next one: hit the first patient date, keep the data clean, and ask the monitor who owns feasibility for the program’s next trial.
Site networks and SMO membership
Site networks and site management organizations pool member sites and pitch them to sponsors as one coverage offer.
| Metric | Range |
|---|---|
| Membership cost | $3,000 to $8,000 a month |
| Awards a year for one member | 2 to 6 |
| Cost per award | about $9,000 to $30,000 |
| Revenue share | common in most arrangements |
Those are estimates, and the spread is wide. A network strong in your indication can fill a calendar. A network strong in someone else’s indication sends you nothing and keeps billing.
Read the member agreement for exclusivity clauses before signing, because some networks restrict what a member may pursue on its own.
Conferences and investigator meetings
The large clinical operations meetings put a lot of feasibility and site selection staff in one building for three days.
What a booth really costs:
- Booth and fees. The largest line.
- Travel for two staff. Three days away from active studies.
- Total. $12,000 to $40,000 for one major meeting, an estimate.
Honest attribution is usually 1 to 3 awards in the following year, so cost per award lands anywhere from $4,000 to $40,000 with a long lag.
The better use of a meeting is booked conversations set up weeks ahead with named people, rather than a badge scan list collected at the booth.
A business development hire
A full-time business development manager with sponsor relationships is the traditional answer, and at a larger site it is the right one.
Fully loaded, the role costs $110,000 to $200,000 a year and produces 6 to 15 awards a year at most sites, an estimate. That is roughly $9,000 to $30,000 per award.
The risk is concentration. The relationships often leave with the person, and a smaller site pays the full salary during the 6 to 12 months before the first award lands.
Buying clinical trial leads
Most products sold as clinical trial leads are patient referral lists for recruitment. They solve a different problem, and they carry consent and health-privacy obligations a site has to verify itself.
The other category is sponsor contact databases at $200 to $1,200 a month. They sell the same static list of clinical operations titles to every subscriber.
Neither tells you which sponsor is short of sites this month.
A contact database is useful as a lookup for a named sponsor. As a prospecting list it produces generic capability emails, and those reply at under 1%.
Trigger-based outbound from the trial registry
Registry-driven outbound has the lowest cost per feasibility conversation of any channel that scales, at about $181 a month in tools, producing 260 to 420 prospects and 8 to 18 feasibility conversations a month, estimates for a site covering 3 to 6 therapeutic areas.
The four records to watch
- Trials not yet recruiting with a start inside 120 days and an enrollment target large against the sites already named.
- Recruiting trials past their primary completion estimate, which is the rescue-site market.
- Clinical-stage financings and registration filings that name a program entering the clinic.
- Study start-up hiring at sponsors and CROs in your therapeutic areas.
The method, in four steps
- Read the registry daily. Every interventional trial run in the US has to be registered before it enrols, and the registry’s API is free.
- Filter to your indications. Match on the MeSH terms as well as the sponsor’s own condition text, and keep studies with no named site in your catchment.
- Find the person who builds the site list. Use the registry’s central contact when one is published, then a feasibility or clinical operations seat.
- Send a short sequence where the first line names the sponsor’s own protocol and your enrolment record in that indication.
“Study NCT number is listed as not yet recruiting with 600 participants and 22 sites named, none in Ohio” gets read. “We are a full-service research site” gets deleted.
What the numbers look like
| Stage | Estimate |
|---|---|
| Reply rate on registry rows | 3 to 7% |
| Reply rate on financing rows | 1 to 3% |
| Replies on 260 to 420 prospects | 8 to 29 |
| Feasibility conversations booked | 8 to 18 |
| Conversation to study award | 12 to 22% |
Rescue rows reply at the top of that range and convert fastest, at 4 to 10 weeks from first email to a contract. Start-up awards take 4 to 9 months to reach first patient in, so judge the channel on a rolling year.
The workflow, the four record feeds, the filter logic, the sequence, and the stack costs are documented in the Clinical Research Site Lead Gen System. It runs on n8n Cloud, it never touches patient records, and you own every piece of it.
Buying lists versus owning a system
A purchased list is a set of titles someone else compiled and sold to every site in the market. It carries no timing, and it stops the day the subscription stops.
An owned system reaches a sponsor while its site list is still open, on a record the sponsor published itself, for a fixed monthly cost that does not rise with volume.
The compounding matters more than the arithmetic.
Every study the system has touched stays under observation, so a trial whose list closed in March comes back the week its completion date slips, and a sponsor that said “not this indication” resurfaces when it registers one that fits.
The registry history quietly becomes an asset nobody can buy:
- Which sponsors run the most trials in your indications
- Which programs slip and need rescue sites
- Which competing sites keep getting named near you
What to do first
Thirty days, in order.
Week 1: build the site profile
Write down what the registry filter needs:
- Therapeutic areas with their full synonym and MeSH term lists
- Catchment as a radius and a list of states
- Thresholds for phase, enrollment target, and patients per listed site
Budget 4 to 8 hours and expect the synonym lists to decide how much volume you find.
Week 2: assemble the enrolment record
For each indication, list the last five comparable protocols:
- Screened and randomized against target
- Screen failure rate
- Days from contract to first patient in
Add de-identified population counts by indication, refreshed monthly as counts only. This is the part a sponsor will check, and the part no competitor can copy.
Week 3: domain, packet, questionnaire habit
- Buy a separate sending domain and start warmup.
- Build the capability packet with investigator CVs, licence and GCP dates, equipment, and start-up timelines.
- Set a rule that every feasibility questionnaire goes back inside 5 business days.
Week 4: send the first 10 by hand
Send the first 10 emails by hand before automating anything, because the opening line has to sound like someone who actually read the protocol.
Then hold a standing review against the numbers in the system spec and change one thing at a time.
